Riskpilot← Back to searchSign inGet full accessNOVAMED A/S
A/SActiveCVR 34589569Gammel Darupvej 5AWholesale of pharmaceutical and medical goods · NACE 4646Est. 20126 employees
Revenue 2024
DKK 6,1M
+31% vs 2023
EBITDA margin
39.0%
+96% vs 2023
Equity ratio
58.6%
Financial strength
Net profit 2024
DKK 1,7M
+189% vs 2023
| Revenue | DKK 6,1M | +31% |
| EBITDA | DKK 2,4M | +96% |
| Net profit | DKK 1,7M | +189% |
| Total assets | DKK 12,3M | +20% |
| Equity | DKK 7,2M | +32% |
| Employees | 6 | — |
Legal name
NOVAMED A/S
CVR number
34589569
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. juni 2012
Share capital
DKK 500.000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør.
Company purpose
Selskabets formål er salg, distribution og agentvirksomhed af lægemiddelprodukter, hospitalsartikler o.l.
Address
Gammel Darupvej 5A
Phone
+4527506806
Email
ura@novamed.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.790 | 5.365 | 8.283 | 2.138 | 3.402 | 3.310 | 6.081 | 7.676 | 5.169 | 8.025 | 4.638 | 6.092 |
| Staff expenses | -0 | -49 | -625 | -678 | -1.035 | -1.431 | -1.462 | -3.021 | -3.143 | -2.383 | -3.327 | -3.428 | -3.717 |
| EBITDA | — | 604 | 1.039 | 1.151 | 1.103 | 1.972 | 1.848 | 3.060 | 4.533 | 2.787 | 4.698 | 1.211 | 2.375 |
| Depreciation & amort. | -0 | -0 | -0 | -6 | -13 | -21 | -68 | -130 | -210 | -226 | -217 | -180 | -119 |
| EBIT | — | 604 | 1.039 | 1.145 | 1.090 | 1.950 | 1.780 | 2.930 | 4.322 | 2.560 | 4.481 | 1.030 | 2.256 |
| Net financials | 0 | -5 | -2 | -11 | 172 | -28 | -134 | -89 | -100 | -191 | -69 | -176 | -14 |
| Profit before tax | — | 599 | 1.036 | 1.134 | 1.262 | 1.922 | 1.646 | 2.841 | 4.223 | 2.369 | 4.412 | 854 | 2.242 |
| Tax | -0 | -0 | 254 | 266 | 280 | 418 | 393 | 654 | 975 | 564 | 997 | 254 | 510 |
| Net profit | — | 599 | 782 | 867 | 982 | 1.504 | 1.252 | 2.188 | 3.248 | 1.806 | 3.415 | 600 | 1.733 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 303 | 941 | 3.449 | 4.291 | 6.662 | 8.155 | 9.307 | 12.658 | 15.210 | 11.745 | 13.996 | 10.265 | 12.290 |
| Equity | 85 | 684 | 1.466 | 2.274 | 3.255 | 2.569 | 3.821 | 5.903 | 7.150 | 4.956 | 8.371 | 5.471 | 7.204 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 154 | 159 |
| Short-term debt | 218 | 257 | 1.983 | 1.917 | 3.406 | 3.587 | 5.478 | 6.724 | 8.023 | 6.770 | 5.625 | 4.639 | 4.927 |
| Total debt | 218 | 257 | 1.983 | 2.017 | 3.406 | 5.587 | 5.478 | 6.724 | 8.023 | 6.770 | 5.625 | 4.793 | 5.086 |
EBITDA margin
39.0%
This company
15.8%
Market median
+147% vs market
20122024
Equity ratio
58.6%
This company
38.2%
Market median
+53% vs market
20122024
Return on equity
24.1%
This company
18.4%
Market median
+31% vs market
20122024
Net profit margin
28.4%
This company
8.1%
Market median
+251% vs market
20122024
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
20122024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-06-08 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UR Management | Management | 2019 | — | — |
FB | Audit | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Rothaus Holding ApS | Company | 100.0% | 100.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rothaus Holding ApS
NOVAMED A/S Board members of NOVAMED A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrich Rothaus Andersen | Management | 0 companies |
| Frank Bergmann Hansen | Audit | 0 companies |
| Anne Stendys | Board of Directors | 0 companies |
| Jacob Rothaus Stendys | Board of Directors | 0 companies |